Drugs / 225Ac-LNC1011
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07117760 | Apr 2025 → Dec 2027 expected | prostate cancer | First Affiliated Hospital of Fujian Medical University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT07363486 | Apr 2025 → Dec 2026 expected | prostate cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-LNC1011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07117760 ↗ |
| Modality | Other / unclassified | “LNC1011 is a novel albumin-binding PSMA-targeted radioligand.” NCT07117760 ↗ |
| Route | Intravenous | “administered intravenously” NCT07117760 ↗ |